Evidence map›Paper›PMID 41852602›Full record

ArticleGynecologic oncology reports2026

Neoadjuvant chemotherapy in locally advanced clear cell carcinoma of the cervix leading to complete disease resolution; a case report.

Emily Fronk, Michelle Whittum, Dijana Poljak, Ashlee Smith

Abstract readCase Reports
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily FronkDepartment of Obstetrics and Gynecology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 668, Rochester, NY 14642, USA.
Michelle WhittumDivision of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Dijana PoljakDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Ashlee SmithDivision of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cervical clear cell carcinoma, a rare form of cervical adenocarcinoma, is traditionally treated with regimens based on those used in more prevalent forms of cervical cancer. However, those with locally advanced disease typically have worse outcomes, likely due to its poor radiosensitivity, raising the question whether alternative treatment regimens should be considered. Methods: This paper presents the case of a 46-year-old female with newly diagnosed locally advanced clear cell cervical carcinoma who underwent treatment with neoadjuvant chemotherapy with cisplatin/paclitaxel/pembrolizumab/bevacizumab followed by radical hysterectomy. Results: Post-treatment imaging and post-operative final pathology specimen showed complete resolution of disease. Conclusions: This is the first report to our knowledge of this novel neoadjuvant treatment regimen for cervical clear cell carcinoma; based on this patient's excellent response, further investigation is needed to clarify the optimal neoadjuvant treatment for patients with this rare and difficult to treat disease.

Identifiers

PMID41852602
PMCPMC12993221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.